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Abstract
Introduction Sodium chlorite is a powerful oxidizing agent
with multiple commercial applications. We report the pre-
sentation and management of a single case of human toxic-
ity of sodium chlorite.
Case report A 65-year-old man presented to hospital after
accidentally ingesting a small amount of a sodium chlorite
solution. His principal manifestations were mild methemoglo-
binemia, severe oxidative hemolysis, disseminated intravas-
cular coagulation, and anuric acute kidney injury. He was
managed with intermittent hemodialysis, followed by contin-
uous venovenous hemofiltration for management of acute
kidney injury and in an effort to remove free plasma chlorite.
Concurrently, he underwent two red cell exchanges, as well as
a plasma exchange, to reduce the burden of red cells affected
by chlorite. These interventions resulted in the cessation of
hemolysis with stabilization of serum hemoglobin and plate-
lets. The patient survived and subsequently recovered normal
renal function.
Discussion This is only the second case of sodium chlorite
intoxication reported in the medical literature and the first to
report the use of renal replacement therapy in combination
with red cell exchange in its management.
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Introduction
Sodium chlorite is a powerful oxidizing agent used to gen-
erate chlorine dioxide, which has several applications, in-
cluding bleaching of pulp, paper, and textiles. When
ingested, oxidizing agents can lead to methemoglobinemia,
and intravascular hemolysis may ensue. Only one case of
sodium chlorite ingestion has been reported in the literature
[1]. We report the only known case of accidental sodium
chlorite ingestion leading to mild methemoglobinemia, se-
vere hemolysis, and acute kidney injury (AKI) successfully
treated with hemodialysis, followed by hemofiltration and
concurrent red cell and plasma exchange.
Case
A 65-year-old man presented to his local hospital with
nausea, vomiting, diarrhea, and dark urine after ingesting a
small amount of a 28 % sodium chlorite solution. He had
diluted the sodium chlorite in a cup with an unmeasured
amount of water and was using this solution to clean his
fruit. He then accidentally drank a mouthful of the solution
after confusing this cup with another that contained only
water. Upon ingestion, he immediately self-induced vomit-
ing, and only after 4 h when he noticed dusky finger tips and
lips, did he present to the hospital. He was transferred to our
institution and, upon arrival, was hemodynamically stable,
mildly confused, and anuric. Initial pertinent laboratory
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results revealed hemoglobin 184 g/L, white blood cell count
22.1×109/L, normal platelet count, creatinine 144 μmol/L,
sodium 141 mmol/L, potassium 5.5 mmol/L, bicarbonate
19 mmol/L, chloride 114 mmol/L, calculated anion gap 14,
ionized calcium 1.13 mmol/L, phosphate 1.37 mmol/L, and
haptoglobin of <0.08 g/L. Bilirubin and lactate dehydrogenase
were unable to be processed by the laboratory, but the serum
was described as being brownish in color. Urine was brown,
and examination showed 3+ hemoglobin, with few red blood
cells and many hemegranular casts. Initial arterial blood gas
showed pH 7.35, paCO2 35 mmHg, paO2 256 mmHg, methe-
moglobin (MetHb) 6.7 %, and lactate 1.8 mmol/L.
He was admitted to the intensive care unit and treated
with an 8-h session of hemodialysis to manage hyperkale-
mia and to attempt removal of sodium chlorite. We used a
high-flux dialysis filter (Toray TS-1.6SL polysulfone filter)
and prescribed a blood flow of 400 mL/min with a dialysate
flow of 500 mL/min to maximize clearance. The dialysate
contained electrolytes in the following concentrations: bi-
carbonate 35 mmol/L, sodium 140 mmol/L, potassium
2 mmol/L, magnesium 0.75 mmol/L, calcium 1.5 mmol/L,
and glucose 8 mmol/L.
Hewas not treated with methylene blue or ascorbic acid but
was started on a high-dose N-acetylcysteine infusion. We used
the 21-h intravenous N-acetylcysteine regimen recommended
in acetaminophen toxicity (150 mg/kg over 1 h, followed by
50 mg/kg over 4 h then 100 mg/kg over 16 h). While on
dialysis, his MetHb levels decreased to normal, but upon its
completion, he developed an increasing lactate (8.2 mmol/L),
a drop in hemoglobin to 87 g/L, and hemodynamic instability
requiring intravenous fluid resuscitation and vasopressor sup-
port with norepinephrine (10 mcg/min). A serum glucose-6-
phosphate dehydrogenase (G6PD) screen revealed deficiency,
and plasma-free hemoglobin was markedly elevated at
1,783 mg/L. A peripheral blood film showed blister and bite
cells consistent with oxidative hemolysis, with no evidence of
microangiopathic hemolysis. It also showed marked thrombo-
cytopenia due to peripheral consumption with platelets of 28×
106/L. In addition to thrombocytopenia, elevated PT INR
(1.4) and D-dimer (15.43 mg/L) were consistent with the
diagnosis of disseminated intravascular coagulation (DIC).
Peak fibrinogen and creatine kinase were 2.2 g/L and
2,926 U/L, respectively.
High FiO2 was delivered via a non-rebreather mask, and
continuous venovenous hemofiltration (CVVH) with a total
effluent of 50 mL/kg was initiated. The filter used was
Gambro ST100 AN69® membrane, and replacement fluid
was Gambro PrismaSol® with electrolyte concentrations as
follows: bicarbonate 32 mmol/L, sodium 140 mmol/L, po-
tassium 3 mmol/L, chloride 108 mmol/L, magnesium
0.5 mmol/L, and lactate 3.0 mmol/L. Concurrently, red cell
exchange was initiated via a separate 12 French dual lumen
central venous catheter. Upon completion of the 2-h long red
cell exchange (total of 3.3 L exchanged), his symptoms
improved, and the lactate and plasma-free hemoglobin
decreased to 4.8 mmol/L and 967 mg/L, respectively,
(Fig. 1). After an initial several hours of stability, his
hemoglobin again dropped to 83 g/L. This was accom-
panied by worsening nausea and back pain, as well as
an increase in lactate to 9.5 mmol/L and a recurrence of
hemodynamic instability. He underwent a second session
of red cell exchange (2 h with total exchange of 2 L),
which was followed by plasma exchange (3.5 h with
5.2 L exchanged). With this exchange, his symptoms
again abated, and his lactate normalized. Plasma-free
hemoglobin decreased to 125 mg/L.
He subsequently remained stable with no further drops in
hemoglobin or rises in lactate. He underwent esophagogas-
troduodenoscopy which revealed only superficial gastric
ulcers. Repeat screens for G6PD deficiency at 4 days and
12 months were negative. He was continued on continuous
renal replacement for 96 h in total at which time he was
transitioned to intermittent hemodialysis as he remained
anuric; 17 days after admission to hospital, he was no longer
dialysis-dependent and was discharged home. Over the fol-
lowing 2 months, his serum creatinine returned to its pre-
morbid level of 94 μmol/L.
Discussion
Sodium chlorite is a white crystal that is readily dissolv-
able in water. Its primary commercial application is that of
a bleaching agent in the pulp and paper and textile indus-
tries. Outside of its commercial uses, it has numerous
unfounded claims as a “natural health” cure for a multi-
tude of health issues.
Fig. 1 Serum hemoglobin, lactate, and plasma-free hemoglobin (PFH)
over time
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Although there is not an abundance of data regarding the
physiologic effects of sodium chlorite, several animal and
human studies have documented its ability to cause methe-
moglobinemia, hemolysis, and glutathione depletion [2].
More physiologic data exist for the related compound, so-
dium chlorate [3, 4]. A study by Singelmann et al. examined
the effect of incubating human red cells with varying con-
centrations of chlorate, showing that these red cells develop
glutathione depletion and methemoglobinemia. In addition,
chlorate led to inhibition of G6PD and increased membrane
rigidity. This drug-induced G6PD deficiency, in addition to
glutathione depletion and membrane rigidity, leads to oxi-
dative hemolysis and explains the lack of efficacy of meth-
ylene blue in these patients [3, 4]. Importantly, Steffen et al.
noted that the presence of methemoglobin was necessary for
inhibition of G6PD and cross-linking of membrane proteins.
If, however, hypochlorite was used instead of chlorate;
oxidation of hemoglobin and oxidative hemolysis occurred
independent of methemoglobin. This feature may explain
the severity of hemolysis in our case, despite the presence of
only mild methemoglobinemia.
Only one previous case of acute sodium chlorite toxicity
has been reported in the literature [1]. Lin et al. described a
case of intentional ingestion of sodium chlorite leading to
severe methemoglobinemia, hemolysis, DIC, and renal fail-
ure. The patient presented with a MetHb level of 59 %,
which did not respond to administration of multiple doses
of methylene blue. He subsequently developed hemolysis
and DIC and was treated with continuous arteriovenous
hemofiltration. He survived and eventually recovered renal
function.
Our patient presented with similar gastric upset, likely as
a result of chlorite-induced irritation of the gastric mucosa.
Unlike the previous case, our patient presented with only
mild methemoglobinemia. Despite this, he developed inhi-
bition of G6PD and went on to suffer life-threatening oxi-
dative hemolysis. This suggests that methemoglobinemia is
not a prerequisite for chlorite-induced enzyme inhibition
and membrane protein cross-linking. Due to the low levels
of MetHb, acute G6PD deficiency, and previous lack of
efficacy reported for chlorate and chlorite ingestions, we
chose not to administer methylene blue or ascorbic acid.
We did, however, employ high-dose N-acetylcysteine in an
attempt to replenish depleted glutathione stores. Although
we had no data to suggest its use, we felt that there was a
theoretical benefit with minimal risk of adverse consequen-
ces. It is unclear what factors contributed to the discrepancy
between MetHb levels and hemolysis in the two cases. It
may be that a smaller ingested amount of chlorite resulted in
less MetHb, although this leaves unexplained the similar
degree of hemolysis in the two cases. It is plausible, as
explained above, that oxidative hemolysis with chlorite
may occur independently of methemoglobinemia.
In the absence of severe methemoglobinemia, we believe
that the intermittent lactic acidosis resulted from a combi-
nation of decreased oxygen-carrying capacity and reduced
tissue perfusion. The patient had hemolyzed more than half
of his red cells, thereby reducing oxygen-carrying capacity
of more than 50 %. In addition, massive hemolysis can lead
to hypotension due to peripheral vasodilation, thereby lead-
ing to reduced tissue perfusion and lactic acidosis [5]. This
explains the simultaneous occurrence of hemolysis, hypo-
tension, and increasing serum lactate levels.
The exact cause of the acute kidney injury is unclear but
is likely multifactorial. Lin et al. reported a diagnosis of
acute interstitial nephritis in a patient with sodium chlorite
toxicity [1]. Findings on renal biopsy included acute tubu-
lointerstitial changes, lymphocytic infiltration, and severe
interstitial edema. They also described moderate tubule
damage with hemorrhage and necrosis along with focally
collapsed loops. However, several of these findings, such as
necrosis, are not usual findings of interstitial nephritis. In
addition, the extremely rapid progression to anuria is not
consistent with interstitial nephritis.
Several studies of chlorate, a chemically similar com-
pound to chlorite, suggest that renal toxicity is due to a
combination of methemoglobinuria, direct proximal tubular
toxicity, and possibly lesions similar to those seen with the
hemolytic uremic syndrome [4, 6]. In the absence of severe
methemoglobinemia, it is likely that the patient’s AKI is
accounted for by a combination of tubular toxicity from
hemoglobin and renal ischemia due to poor oxygen delivery.
The renal medulla has a very low oxygen tension in normal
conditions and is, therefore, extremely sensitive to reduced
systemic oxygen delivery. Cases of renal failure with other
forms of oxidative hemolysis support this theory [7].
With a molecular weight of 67.45 daltons, unbound chlo-
rite should be effectively removed by hemodialysis with a
standard or high-flux dialysis membrane. Our patient’s he-
moglobin and hemodynamics remained stable while receiv-
ing IHD, which we theorize may be related to removal of
free chlorite. It is important to note that the amount of free
versus bound chlorite in serum is unknown, and that hemo-
dialysis was undertaken both to manage AKI and in an
attempt to remove any free chlorite. It is difficult to know
whether or not extracorporeal removal of chlorite played a
significant role in improving the patient’s outcome, and it
remains possible that it was of little benefit.
In trying to remove small toxins, such as chlorite, high
efficiency clearance achieved with intermittent hemodialysis
dictates that this be the modality of choice. The volume of
distribution of chlorite is unknown; therefore, a prolonged
session of intermittent dialysis, similar to that used in a
lithium overdose, is prudent.
Our patient developed worsening hemolysis after com-
pletion of a session of intermittent hemodialysis, which we
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suspected was due to a rebound increase in serum chlorite
levels secondary to redistribution from the extravascular
space. Due to intermittent hemodynamic instability and in
an attempt to avoid rebound increases in serum chlorite
levels, continuous renal replacement therapy was initiated.
We prescribed a relatively high dose of CVVH (50 mL/kg)
to maximize clearance of chlorite. Pure hemofiltration was
chosen over dialysis in an effort to enhance clearance of free
hemoglobin and limit renal tubular damage. It is, however,
unlikely that removal of free hemoglobin altered the course
of AKI as the patient was already anuric.
Although not previously used in chlorite intoxication, red
cell exchange has been used in numerous chlorate ingestions,
with variable success [6, 8]. We undertook red cell exchange
to reduce the burden of red cells affected by chlorite. Indeed,
the patient did significantly improve with this intervention. It
is unclear if his subsequent deterioration was due to residual
abnormal red cells, serum chlorite affecting transfused red
cells, or progressive DIC from the persistent presence of
hemolytic waste products in the plasma [6]. A second red cell
exchange was therefore performed together with a plasma
exchange, resulting in cessation of hemolysis and continued
physiologic stability.
In conclusion, it is important to consider sodium chlorite
ingestion when encountered by a patient with hemolysis, with
or without methemoglobinemia. Methylene blue is ineffective
for reducing MetHb. Although no clinical evidence exists for
its use, high-dose N-acetylcysteine may be considered for its
theoretical benefit along with minimal risk.
This is the first reported case of sodium chlorite toxicity
managed with hemodialysis, hemofiltration, and concurrent
red cell and plasma exchange. Without larger case series or
prospective studies, it is difficult to suggest this as standard
of care; but with physiologic reasoning, our successful pa-
tient outcome, and minimal risk, it should be strongly con-
sidered in the critically ill patient with related exposure.
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